Quality of life in schizophrenia: A multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics

Journal of Clinical Psychiatry

Volumn 66, Issue 7, 2005, Pages 831-838

  De Lima, Maurício Silva ^a,b   De Jesus Mari, Jair ^c,d   Breier, Alan ^e   Costa, Anna Maria ^a,c,h   De Sena, Eduardo Pondé ^f   Hotopf, Matthew ^g  

^a Eli Lilly Brazil   (Brazil)

^b FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d CATHOLIC UNIVERSITY OF PELOTAS   (Brazil)

^e ELI LILLY AND COMPANY   (United States)

^f FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TRIFLUOPERAZINE;

ADULT; ARTICLE; BODY MASS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HEALTH SURVEY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 22744457230     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0704     Document Type: Article

References (29)

1. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia [Published correction appears in J Clin Psychiatry 1997;58:275]. J Clin Psychiatry 1997;58:205-211
2. Duggan L, Fenton M, Dardennes RM, et al. Olanzapine for schizophrenia. In: The Cochrane Library, Issue 2, 2003. Chichester, England: Wiley
3. Kennedy E, Song F, Hunter R, et al. Risperidone versus typical antipsychotic medication for schizophrenia. In: The Cochrane Library, Issue 2, 2003. Chichester, England: Wiley
4. Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. In: The Cochrane Library, Issue 2, 2003. Chichester, England: Wiley
5. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. In: The Cochrane Library, Issue 2, 2003. Chichester, England: Wiley
6. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
7. Patrick DL, Erickson P. Assessing health-related quality of life for clinical decision-making. In: Walker SR, Rosser RM. Quality of Life Assessment. London, UK: Kluwer Academic Publishers; 1993:11-63
8. Sanders C, Egger M, Donovan J, et al. Reporting on quality of life in randomised controlled trials: a bibliographic study. BMJ 1998;317: 1191-1194
9. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967;20:637-648
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
11. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
12. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
13. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36), 1: conceptual framework and item selection. Med Care 1992;30:473-483
14. Guy W, ed. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmcology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
15. Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997;22:256-266
16. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1991
17. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167
18. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-920
19. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
20. Jakovljevic M, Dossenbach MRK, Friedel, P, et al. Olanzapine versus fluphenazine in the acute (six-week) treatment of schizophrenia. Psychiatr Danub 1999;11:3-10
21. Davis J, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
22. Tunis SL, Croghan TW, Heilman DK, et al. Reliability, validity, and application of the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 1999;37:678-691
23. Beasley CM Jr, Dellva MA, Tamura RN, et al. Randomized, double-blind comparison of the incidence of tardive dyskinesia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30
24. Mraz K, Gogus A, Tunca Z, et al. Olanzapine versus chlorpromazine in Turkey [abstract]. Schizophr Res 2000;41:190
25. Loza N, El-Dosoky AM, Okasha TA, et al. Olanzapine compared to chlorpromazine in acute schizophrenia. Eur Neuropsychopharmacol 1999;9(suppl 5):S291
26. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-474
27. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100
28. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotics drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-1404
29. Hotopf M, Churchill R, Lewis G. Pragmatic randomised controlled trials in psychiatry. Br J Psychiatry 1999;175:217-223